Key result
TAVI shows similar 30-day composite outcomes to SAVR with shorter stays but higher costs.
Why the study?
TAVI has emerged as a preferred treatment for severe, symptomatic aortic stenosis, but comparative clinical and cost data against surgical aortic valve replacement (SAVR) within the Brazilian public health system (SUS) remain limited.
Does transcatheter aortic valve implantation (TAVI) improve periprocedural clinical outcomes and reduce direct medical costs compared to surgical aortic valve replacement (SAVR) in patients with severe symptomatic aortic stenosis in the Brazilian public health system?
Observational (n=320)
No
Does transcatheter aortic valve implantation (TAVI) improve periprocedural clinical outcomes and reduce direct medical costs compared to surgical aortic valve replacement (SAVR) in patients with severe symptomatic aortic stenosis in the Brazilian public health system?
In a Brazilian public health system tertiary hospital, TAVI achieved similar 30-day clinical outcomes and shorter hospital stays compared to SAVR despite treating older and higher-risk patients, though at more than double the total direct medical cost due to device expenses.
Answers are grounded in this paper and cite their sources.
TAVI may support shorter stays with similar short-term outcomes in higher-risk patients; leaves open cost-effectiveness for public-system adoption.
Background Transcatheter aortic valve implantation (TAVI) has emerged as a preferred treatment for severe, symptomatic aortic stenosis (AS). However, comparative data with surgical aortic valve replacement (SAVR) within the Brazilian public health system (SUS) remain limited. Objective To compare clinical outcomes and perform a cost-analysis of TAVI versus SAVR in SUS patients. Methods This retrospective, single-center study evaluated clinical outcomes and direct medical costs, using a statistical significance threshold of 5%. Results Between 01/2018 and 12/2022, 320 patients (139 TAVI, 181 SAVR) were included. TAVI patients were older (77.9 vs. 64.9 years, p<0.001) and had higher surgical risk (STS 3.62% vs. 1.64%, p<0.001). Mortality (2.9% vs. 5.0%) and stroke rates (1.4% vs. 3.3%) were numerically lower for TAVI, but not statistically significant. In a risk-adjusted composite outcome (death, stroke, re-hospitalization), TAVI showed potential superiority (5.8% vs. 12%, OR 2.68, 95% CI 1.04-7.65, p=0.05), though not statistically significant. TAVI was associated with a shorter hospital stay (2.0 vs. 8.0 days, p<0.001). TAVI’s total cost was significantly higher than SAVR’s (R$ 55,750.90 [52,345.30; 92,286.80] vs R$ 22,518.10 [19,130.60; 25,875.10, - p<0.001]). Conclusions In this study, TAVI displayed similar clinical outcomes compared to SAVR, while being performed on older patients with higher surgical risk. From an economic perspective, costs of TAVI treatment were significantly higher than SAVR, driven mainly by device costs, while in-hospital length of stay was significantly lower. With extended follow-up and reduced procedural costs, TAVI may become a cost-effective option in the SUS.
No takes yet. Share an insight, caveat, or question.
Saad et al. (2025) conducted an observational in Severe, symptomatic aortic stenosis (n=320). Transcatheter aortic valve implantation (TAVI) vs. Surgical aortic valve replacement (SAVR) was evaluated on Risk-adjusted 30-day composite of all-cause death, stroke, or re-hospitalization (OR 2.68, 95% CI 1.04-7.65, p=0.05). TAVI showed similar 30-day composite outcomes to SAVR and shorter hospital stays, but higher total costs.
Synapse has enriched 10 related papers. Consider them for comparative context: